Study guide

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back

Key Takeaways Explain This Topic AI

Educate is 25% of the CARN-AP blueprint, roughly 37 to 38 items, more than the 16% assigned to pharmacological prescribing.

Teach-back asks the patient to restate the plan in their own words and explicitly frames any gap as the teacher's failure, not the learner's.

Written patient materials should target a fifth- to sixth-grade reading level, and the Ask Me 3 questions structure the essential content of any teaching encounter.

The highest-rated education activity in the 2025 practice analysis was providing information about intended effects and potential adverse events of proposed prescriptive treatments, with a mean index of 11.05.

Health literacy should be addressed universally through plain language rather than by attempting to identify which patients have limited literacy.

Last updated: September 2026

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back

Quick Answer: Activity Area III — educate patients, families (support systems), other health professionals and the public — is 25% of the CARN-AP examination (37 to 38 items) , exceeding the 16% assigned to pharmacological prescribing. Its highest-rated activity is "provides healthcare consumers with information about intended effects and potential adverse events of proposed prescriptive treatments" (mean index 11.05). Effective teaching uses plain language universally , targets a fifth- to sixth-grade reading level in written materials, tailors content to developmental level, health literacy, readiness to learn and cultural values , and confirms understanding with teach-back .

1. Universal Precautions for Health Literacy

Clinicians are poor at predicting which patients have limited health literacy. Education level, vocabulary and professional background all mislead, and patients with limited literacy frequently conceal it. The evidence-based response is universal precautions : assume that any patient may have difficulty, and structure every encounter accordingly.

  • Practice What it looks like
  • Plain language "Medicine that blocks the effect of opioids" instead of "opioid antagonist"
  • Limited chunks Two to three key points per encounter, not eight
  • Slow down Deliberately reduce pace; pause after each point
  • Concrete instructions "Take one tablet when you wake up" instead of "once daily"
  • Show, don't tell Demonstrate naloxone assembly; hand the patient the device
  • Written backup Fifth- to sixth-grade reading level, large type, white space, images
  • Teach-back Confirm comprehension before the encounter ends
  • Ask Me 3

Three questions that organize the content of any teaching encounter, and that patients can be taught to ask:

What is my main problem?

What do I need to do?

Why is it important for me to do this?

2. Teach-Back Done Correctly

Teach-back is not "Do you understand?" or "Any questions?" — both reliably produce a yes from patients who have understood nothing. The method:

Frame it as a check on yourself. "I want to make sure I explained this well. Can you tell me in your own words how you'll take this medicine?"

Ask for a demonstration where possible. "Show me how you'd put the film under your tongue."

If the patient cannot restate it, re-teach differently — not louder, not the same words. Use a drawing, a different analogy, or a written aid.

Repeat until the patient can restate accurately. Document that teach-back was performed and what the patient demonstrated.

Why the framing matters: attributing a comprehension gap to your explanation rather than to the patient removes shame, and shame is the reason patients nod along. In addiction care, where patients arrive already expecting judgment, this framing is doubly important.

3. Tailoring to Developmental Level, Readiness and Culture

The practice analysis explicitly names "designs healthcare consumer education appropriate to their developmental level, health literacy, learning needs, readiness to learn, and cultural values and beliefs." Four tailoring axes:

Axis Practical adjustment

Developmental level Adolescents respond to autonomy and short-term social consequences, not mortality statistics; older adults need larger type, slower pace, and attention to sensory and cognitive changes

Health literacy and numeracy Replace percentages with frequencies ("about 1 in 10 people") and avoid "risk reduction" framing that requires baseline knowledge

Readiness to learn A patient in acute withdrawal, acute pain or acute crisis cannot encode new information. Teach the single safety-critical item now and schedule the rest

Cultural values and beliefs Ask what the patient and family believe caused the problem and what they think will help, then build teaching around that model rather than against it

Working with interpreters

Use a qualified medical interpreter , not a family member and never a child. Speak to the patient , not the interpreter. Use short segments. Confirm with teach-back through the interpreter , since comprehension and translation are separate failure points.

4. Motivational Framing of Educational Content

Information alone rarely changes behavior, and unsolicited advice frequently produces resistance. The elicit-provide-elicit structure integrates education with motivational interviewing:

Elicit: "What do you already know about buprenorphine?" This surfaces misinformation and establishes a starting point.

Provide: Ask permission, then deliver a small, neutral piece of information. "Would it be okay if I shared what we know about how it affects overdose risk?"

Elicit: "What do you make of that?" This invites the patient to do the interpretive work, which is what produces change talk.

5. Timing and Reinforcement

Teach at the moment of relevance. Naloxone teaching lands during a discussion of a friend's overdose, not during an admission checklist.

Repeat across contacts. Single-exposure teaching is reliably forgotten; the practice analysis notes anticipatory guidance and repetition as distinct activities.

Include the support system whenever the patient consents — a family member who understands the plan is a durable reinforcement mechanism, and family members are frequently the ones who will use the naloxone.

Evaluate health information sources. The practice analysis includes "evaluates health information resources, such as the internet, for accuracy, readability, and comprehensibility." Patients arrive with content from social media and forums; part of the APRN's job is helping them judge sources rather than simply contradicting them.

6. Documentation That Demonstrates Education

A defensible education note records: what was taught, in what form (verbal, written, demonstration), who was present, whether an interpreter was used and their identifier, what the patient restated on teach-back, what barriers were identified, and what will be reinforced at the next visit. That structure also satisfies the informed-consent documentation requirement for medication teaching covered in the next section.